LPS-mediated effects and spatio-temporal expression of TLR2 and TLR4 in the bovine corpus luteum by Lüttgenau, Johannes et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
LPS-mediated effects and spatio-temporal expression of TLR2 and TLR4 in
the bovine corpus luteum
Lüttgenau, Johannes; Herzog, Kathrin; Strüve, Klaas; Latter, Sophie; Boos, Alois; Bruckmaier, Rupert
M; Bollwein, Heiner; Kowalewski, Mariusz Pawel
Abstract: When given intravenously (iv), lipopolysaccharide (LPS) transiently suppresses the structure
and function of the bovine corpus luteum (CL). This is associated with increased release of prostaglandin
(PG) F2￿ metabolite (PGFM). The underlying regulatory mechanisms of this process remain, however,
obscure. Therefore, the aims of this study were: (1) to investigate the expression of the LPS receptor
toll-like receptor (TLR) 4 and TLR2 in the bovine CL during early, mid, and late luteal phases; (2) to
further dissect the mechanisms of LPS-mediated suppression of luteal function. As revealed by semi-
quantitative qPCR and immunohistochemistry, both receptors were detectable throughout the luteal
lifespan. Their mRNA levels increased from the early towards the mid-luteal phase; no further changes
were observed thereafter. The TLR4 protein seemed more highly represented than TLR2. The cellular
localization of TLRs was in blood vessels; weaker signals were observed in luteal cells. Additionally, cows
were treated either with LPS (iv, 0.5 µg/kgBW) or with saline on Day 10 after ovulation. Samples were
collected 12 h after treatment, and on Day 10 of the respective subsequent (untreated) cycle. The mRNA
expression of several possible regulatory factors was investigated, revealing the suppression of PGF2￿
receptor (PTGFR), steroidogenic acute regulatory protein (STAR) and 3￿-hydroxysteroid dehydrogenase
(3￿HSD), compared with controls and subsequent cycles. The expression of TLR2 and TLR4, interleukin
(IL) 1￿ and IL1￿, and of PGF2￿ and PGE2 synthases (20￿HSD/PGFS and mPTGES, respectively) was
increased. The results demonstrate the presence of TLR2 and TLR4 in the bovine CL, and implicate
their possible involvement in the deleterious effects of LPS on its function.
DOI: https://doi.org/10.1530/REP-15-0520
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-121109
Accepted Version
Originally published at:
Lüttgenau, Johannes; Herzog, Kathrin; Strüve, Klaas; Latter, Sophie; Boos, Alois; Bruckmaier, Rupert
M; Bollwein, Heiner; Kowalewski, Mariusz Pawel (2016). LPS-mediated effects and spatio-temporal
expression of TLR2 and TLR4 in the bovine corpus luteum. Reproduction, 151:391-399.
DOI: https://doi.org/10.1530/REP-15-0520
1 
 
LPS-mediated effects and spatio-temporal expression of TLR2 and TLR4 in the bovine 1 
corpus luteum 2 
 3 
Lüttgenau J
1,
*, Herzog K
2
, Strüve K
2
, Latter S
3
, Boos A
3
, Bruckmaier RM
4
, Bollwein H
1,#
, 4 
Kowalewski MP
3,#
 5 
 6 
1
Clinic of Reproductive Medicine, Vetsuisse Faculty, University of Zurich, Switzerland 7 
2
Clinic for Cattle, University of Veterinary Medicine Hannover, Germany 8 
3
Institute of Veterinary Anatomy, Vetsuisse Faculty, University of Zurich, Switzerland 9 
4
Veterinary Physiology, Vetsuisse Faculty, University of Bern, Switzerland 10 
 11 
*Corresponding author: 12 
Lüttgenau J 13 
Clinic of Reproductive Medicine, Vetsuisse Faculty, University of Zurich, 14 
Winterthurerstrasse 260, CH-8057 Zurich, Switzerland 15 
Tel.: +41 44 635 90 93 16 
Fax: +41 44 635 89 04 17 
E-mail: jluettgenau@vetclinics.uzh.ch 18 
 19 
# Both authors contributed equally. 20 
 21 
Short title: Spatio-temporal expression of luteal TLR2 and TLR4 22 
Page 1 of 35
 Reproduction Advance Publication first posted on 13 January 2016 as Manuscript REP-15-0520
 Copyright © 2016 by the Society for Reproduction and Fertility.
2 
 
Abstract 23 
When given intravenously (iv), lipopolysaccharide (LPS) transiently suppresses the structure 24 
and function of the bovine corpus luteum (CL). This is associated with increased release of 25 
prostaglandin (PG) F2α metabolite (PGFM). The underlying regulatory mechanisms of this 26 
process remain, however, obscure. Therefore, the aims of this study were: (1) to investigate 27 
the expression of the LPS receptor toll-like receptor (TLR) 4 and TLR2 in the bovine CL 28 
during early, mid, and late luteal phases; (2) to further dissect the mechanisms of LPS-29 
mediated suppression of luteal function. As revealed by semi-quantitative qPCR and 30 
immunohistochemistry, both receptors were detectable throughout the luteal lifespan. Their 31 
mRNA levels increased from the early towards the mid-luteal phase; no further changes were 32 
observed thereafter. The TLR4 protein seemed more highly represented than TLR2. The 33 
cellular localization of TLRs was in blood vessels; weaker signals were observed in luteal 34 
cells. Additionally, cows were treated either with LPS (iv, 0.5 µg/kgBW) or with saline on 35 
Day 10 after ovulation. Samples were collected 12 h after treatment, and on Day 10 of the 36 
respective subsequent (untreated) cycle. The mRNA expression of several possible regulatory 37 
factors was investigated, revealing the suppression of PGF2α receptor (PTGFR), steroidogenic 38 
acute regulatory protein (STAR) and 3β-hydroxysteroid dehydrogenase (3βHSD), compared 39 
with controls and subsequent cycles. The expression of TLR2 and TLR4, interleukin (IL) 1α 40 
and IL1β, and of PGF2α and PGE2 synthases (20αHSD/PGFS and mPTGES, respectively) was 41 
increased. The results demonstrate the presence of TLR2 and TLR4 in the bovine CL, and 42 
implicate their possible involvement in the deleterious effects of LPS on its function. 43 
 44 
Key words: corpus luteum, toll-like receptor, inflammation, endotoxin, cow45 
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1. Introduction 46 
Inflammatory diseases, especially of the uterus and the mammary gland, reduce fertility in 47 
dairy cows (Hansen et al. 2004, Sheldon et al. 2009a). Infertility or subfertility in cows with 48 
uterine inflammation might be exclusively due to local effects in some cases, whereas a 49 
systemic inflammatory response is required to decrease fertility in cows with inflammation 50 
outside the genital tract, e.g., mastitis (Hansen et al. 2004). A systemic inflammatory response 51 
due to bovine metritis and mastitis is often associated with the presence of lipopolysaccharide 52 
(LPS), the endotoxin of gram-negative bacteria (Bannerman et al. 2004, Williams et al. 53 
2005). There is increasing evidence that, at least in part, Escherichia (E.) coli LPS causes 54 
infertility by interfering with ovarian function (Suzuki et al. 2001, Herath et al. 2007, Lavon 55 
et al. 2008). 56 
Ovarian dysfunction due to LPS in cows with inflammatory diseases might be due to 57 
impairment of the hypothalamic-pituitary axis and interference with ovarian follicular and 58 
luteal function (Hansen et al. 2004). Thus, cows with uterine infections after parturition were 59 
less likely to ovulate, probably because of slower growth of dominant follicles, lower 60 
peripheral estradiol (E2) concentrations, and perturbation of hypothalamic and pituitary 61 
function (Sheldon et al. 2009b). LPS was found in the follicular fluid of such animals, likely 62 
additionally contributing to the delay in ovulation (Sheldon et al. 2009b). Similar effects 63 
associated with a delayed LH surge and the resulting postponed ovulation were observed after 64 
intravenous or intramammary administration of LPS in cows (Lavon et al. 2008). 65 
Furthermore, intravenous treatment with LPS transiently suppressed progesterone (P4) 66 
secretion by the bovine corpus luteum (CL) and increased plasma concentrations of 67 
prostaglandin (PG) F2α metabolites (PGFM) (Herzog et al. 2012). Cows with uterine 68 
infections after parturition had increased concentrations of LPS, not only in the uterine fluid, 69 
but also in plasma and follicular fluid (Mateus et al. 2003, Williams et al. 2007, Magata et al. 70 
2015). Thus, it may be assumed that LPS directly reaches the CL. Indeed, since LPS induced 71 
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apoptosis in luteal cell cultures (Grant et al. 2007, Mishra & Dhali 2007), the possibility of a 72 
direct effect of LPS on the bovine CL should be considered. The direct effects of LPS on 73 
target organs depend, however, on the local presence of its specific receptor, toll-like receptor 74 
(TLR) 4 (Gerold et al. 2007, Kannaki et al. 2011), the mRNA expression of which has 75 
recently been shown in the bovine mid-cycle CL (Lüttgenau et al. 2016). 76 
Whereas TLR2 recognizes bacterial lipids such as lipoteichoic acid and peptidoglycan from 77 
gram-positive bacteria, TLR4 in a complex with its co-receptors cluster of differentiation 78 
(CD) 14 and myeloid differentiation factor (MyD) 2 binds LPS, leading to signal transduction 79 
and activation of the innate immune system (Beutler 2004). However, expression of both 80 
TLR2 and TLR4 mRNA increased in bovine mammary (Ibeagha-Awemu et al. 2008, Ma et al. 81 
2011) and endometrial epithelial cells (Fu et al. 2013) stimulated with LPS. Furthermore, 82 
these studies indicate that TLR4 is present on cells other than leukocytes. In cows, TLR4 83 
mRNA and protein were detected in endometrial stromal and epithelial cells by RT-PCR and 84 
flow cytometry (Herath et al. 2006). Activation of TLRs by LPS was observed in endometrial 85 
(Fu et al. 2013) as well as in mammary epithelial cells (Ibeagha-Awemu et al. 2008), thus 86 
inducing the downstream signaling cascade that culminates in the secretion of 87 
proinflammatory cytokines. In bovine granulosa cells, TLR4 was detected and an 88 
inflammatory response to LPS was observed and linked to reduced fertility, due to reduced 89 
follicular steroidogenesis (Herath et al. 2007). Since murine granulosa cells increased the 90 
expression of TLR4 in response to LPS challenge (Shimada et al. 2006), granulosa cells seem 91 
to have immune capabilities (Herath et al. 2007). However, to the best of our knowledge, 92 
there are no reports available describing the spatio-temporal expression of TLR2 and TLR4 93 
on the protein level in the bovine CL. 94 
Consequently, the aims of the present study were: (1) to provide evidence for the expression 95 
of TLR2 and TLR4 in the bovine CL throughout the luteal phase, to determine their cellular 96 
localization; and (2) using samples derived from our previous study (Herzog et al. 2012), to 97 
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further characterize the underlying mechanisms of transient suppression of luteal function 98 
after intravenous LPS-treatment by analysing the mRNA expression of cytokines and factors 99 
associated with prostaglandin synthesis and steroidogenesis. Expression analyses in the 100 
subsequent cycles (after the treated cycles) were aimed at detecting possible carry-over effects 101 
of LPS.102 
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2. Materials and Methods 103 
 104 
2.1. Study 1: Expression of TLR2 and TLR4 in bovine CL throughout the luteal phase 105 
2.1.1. Corpus luteum collection 106 
Ovaries with CL were harvested from the carcasses of fourteen (n=14) clinically healthy cows 107 
(Bos taurus), including Red Holstein (n=12), Holstein Friesian (n=1), and Red Holstein x 108 
Limousin crossbred (n=1), that were slaughtered at a commercial abattoir. Before slaughter, 109 
cows were housed in a tie stall barn, and a modified ovulation synchronization (Ovsynch) 110 
protocol was started (at different times) after normal cyclic activity had been 111 
ultrasonographically confirmed in each cow. The protocol consisted of 10 µg buserelin 112 
(GnRH analog, Receptal®; MSD Animal Health GmbH, Luzern, Switzerland), 15 mg 113 
luprostiol (PGF2α analog, Prosolvin®; Virbac AG, Glattbrugg, Switzerland) 7 days (d) later, 114 
and finally 10 µg buserelin 60 hours (h) after PGF2α (all treatments were given 115 
intramuscularly). Ovulation occurred in all cows within 36 h after the second GnRH 116 
treatment. Starting 17 d after ovulation, transrectal B-mode ultrasonography was performed in 117 
all cows at 2-d intervals to detect the time of ovulation (Day 1), and subsequently every 2 to 118 
3 d to monitor normal development of the CL. Blood sampling and ultrasonography (B-mode 119 
and Power mode) of the CL were performed within 6 h before the cows were slaughtered (at 120 
different cycle stages), and ovaries with CL were collected from the carcasses. For each cow, 121 
the time points during the luteal phase were randomly selected and allotted to the following 122 
groups according to Miyamoto et al. (2000): early (Days 5 to 7; n=4), mid (Days 8 to 12; n=5) 123 
or late (Days 13 to 18; n=5) luteal phase. 124 
 125 
2.1.2. Collection of blood and analysis of progesterone 126 
Blood samples were collected from the coccygeal blood vessels into evacuated tubes 127 
containing EDTA as anticoagulant (Vacuette® 9ml K3EDTA; Greiner bio-one, 128 
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Kremsmünster, Austria). Tubes were immediately placed in ice and plasma was separated by 129 
centrifugation (3,000 x g, 15 min), and frozen at -20 °C until analyses were performed. 130 
Concentrations of P4 were measured using a radioimmunoassay (RIA kit IM1188; Beckman 131 
Coulter GmbH, Krefeld, Germany). The range of standard concentrations for this test was 132 
0.03 to 53 ng/mL, intra- and inter-assay coefficients of variation were ≤8.5% and ≤8.7%, 133 
respectively, and 50% of relative binding was reached at 1.6 ng/mL. 134 
 135 
2.1.3. Ultrasonography 136 
Transrectal ultrasonographic examinations of the uterus and ovaries were performed using a 137 
portable ultrasound device (GE LOGIQ e Premium BT11; General Electric Medical System, 138 
Solingen, Germany), equipped with a 4.0 to 12.0 MHz linear-array transducer. B-mode and 139 
Power Mode ultrasonography and a computer-assisted image analysis software (PixelFlux 140 
Version 1.0; Chameleon Software, Leipzig, Germany) were applied to determine luteal tissue 141 
area (LTA), luteal blood flow (LBF), and relative LBF (rLBF; LBF divided by LTA). A 142 
detailed description of the methodology was provided in previous studies (Lüttgenau et al. 143 
2011a, Lüttgenau et al. 2011b). In cows showing ovulation of two dominant follicles between 144 
Days 0 and 1 (double ovulation), and subsequent development of two CLs, their sum was 145 
applied for luteal measurements, as suggested by Bollwein et al. (2002). 146 
 147 
2.1.4. Preparation of luteal tissue 148 
Immediately after collection, the CL was removed from the ovary, trimmed of connective 149 
tissue, incubated for 24 h in RNAlater® (Ambion Biotechnologie GmbH, Wiesbaden, 150 
Germany) at 4 °C, and finally stored at -80 °C until analysis. For immunohistochemistry 151 
(IHC), tissue samples were fixed for 24 h in 10% neutral phosphate-buffered formalin, 152 
washed with phosphate-buffered saline (PBS), dehydrated in a graded ethanol series, and 153 
embedded in paraffin-equivalent Histo-Comp® (Vogel Medizintechnik, Giessen, Germany). 154 
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 155 
2.1.5. Expression analysis 156 
Luteal mRNA expression was determined for TLR2, TLR4, steroidogenic acute regulatory 157 
protein (STAR) and 3β-hydroxysteroid dehydrogenase (3βHSD). Accordingly, total RNA 158 
from luteal tissue samples was isolated using TRIzol® reagent following the manufacturer’s 159 
protocol (Invitrogen, Carlsbad, CA, USA) and as described in Kowalewski et al. (2013). 160 
Semi-quantitative real time (TaqMan) PCR was carried out in an automated fluorometer ABI 161 
PRISM® 7500 Sequence Detection System (Applied Biosystems by Thermo Fisher, Foster 162 
City, CA, USA) according to a previously described protocol (Kowalewski et al. 2006). 163 
Samples were run in duplicates with Fast Start Universal Probe Master (ROX)® from Roche 164 
Diagnostics (Mannheim, Germany). Autoclaved water instead of RNA and the so called RT 165 
minus control were used as negative controls. Integrity of RNA and the assay procedure were 166 
tested by amplification of different independent endogenous references (SDHA, GAPDH and 167 
βACTIN). The assays were set up to ensure approximately 100% efficiency of the PCR 168 
reactions. Relative gene expression was calculated using the comparative CT method (∆∆CT 169 
method) according to the manufacturer’s protocols for the ABI PRISM® 7500 Sequence 170 
Detection System (Applied Biosystems) and as described previously (Kowalewski et al. 2006, 171 
Kowalewski et al. 2011). 172 
Specificity of the selected PCR products was confirmed by sequencing (Microsynth, Galbach, 173 
Switzerland). A detailed description of the RT-qPCR method is provided in Kowalewski et al. 174 
(2006, 2011, 2013). The primers used to amplify specific fragments referring to selected 175 
genes purchased either from Microsynth or from Applied Biosystems are presented in 176 
Table 1. 177 
 178 
2.1.6. Immunohistochemistry (IHC) 179 
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Methods of indirect immunoperoxidase IHC were described in detail by Kowalewski et al. 180 
(2006, 2011, 2013). In brief, luteal cross sections (2-3 µm thick) were cut and mounted on 181 
Super-Frost-Plus microscope slides. Antigen retrieval was done using citrate buffer (pH 6.0). 182 
Non-specific binding sites were blocked with normal 10% goat serum. The following 183 
antibodies were used: affinity purified polyclonal rabbit anti-TLR2 (Biorbyt, Cambridge, 184 
UK), and affinity purified polyclonal rabbit anti-TLR4 (Abbiotec, San Diego, CA, USA). The 185 
concentration of both primary antibodies was 1:200. Rabbit IgG (Vector Laboratories, Ltd., 186 
Burlingame, CA, USA) was used at the same protein concentration as the isotype specific 187 
negative control. The secondary antibody was biotinylated goat anti-rabbit IgG (BA-1000) 188 
from Vector Laboratories, Ltd. (dilution 1:100). Peroxidase activity was visualized using the 189 
DAB substrate kit (Dako Schweiz AG, Baar, Switzerland) and slides were counterstained 190 
with hematoxylin. 191 
 192 
2.2. Study 2: LPS-induced alterations in the expression of TLR2, TLR4 and other luteal 193 
factors 194 
2.2.1. Corpus luteum biopsies 195 
Corpus luteum biopsies from a previous experiment (Herzog et al. 2012) were used. In that 196 
study, transrectal ultrasonography was performed in each of seven clinically healthy, non-197 
lactating German Holstein cows (Bos taurus) at 12, 24, and 36 h after the second GnRH 198 
treatment of a modified Ovsynch protocol to detect the time of ovulation (defined as Day 1 of 199 
the estrous cycle). On Day 10, cows were treated with 10 mL saline (NaCl 0.9%; iv, during 1-200 
min), and luteal tissue was collected for biopsy 12 h after treatment and additionally on 201 
Day 10 of the subsequent (untreated) cycle. Then, the Ovsynch protocol was repeated, and 202 
cows were treated with 0.5 µg/kg body weight E. coli LPS (O55:B5; Sigma-Aldrich, 203 
Taufkirchen, Germany; diluted in 10 mL sterile water; iv, during 1-min) on Day 10 of the 204 
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estrous cycle. Again, collection of luteal tissue was performed at 12 h after treatment and on 205 
Day 10 of the subsequent (untreated) cycle. 206 
The collection of biopsy samples (approximately 15 x 1 x 1 mm each) from the maximum 207 
diameter (including cells from the periphery and the center) of the CL was performed using a 208 
semi-automatic, high-speed biopsy needle (TEMNO Evolution™; Fa. Walter, Baruth/Mark, 209 
Germany) as described previously (Herzog et al. 2012).  210 
This method allowed repeated biopsy sampling from a single CL without impairing its 211 
subsequent function (Tsai et al. 2001, Atli et al. 2012). 212 
 213 
2.2.2. Expression analysis 214 
Semi-quantitative real time PCR was applied for investigating the mRNA expression levels of 215 
target genes: TLR2, TLR4, STAR, 3βHSD, cyclooxygenase 2 (COX2, PTGS2), PGE2 synthase 216 
(mPTGES), PGF2α synthase (20αHSD/PGFS), PGF2α receptor (PTGFR, FP), fibroblast 217 
growth factor 1 (FGF1) and -2 (FGF2), interleukin (IL) 1α and IL1β, interleukin 1 receptor 218 
(IL1R1), tumor necrosis factor α (TNFα), TNF receptor 1 (TNFR1) and -2 (TNFR2). The 219 
methodological approach was as presented above for Study 1. The primers and TaqMan 220 
probes sequences were purchased from Microsynth (Galbach, Switzerland) and are presented 221 
cumulatively in Table 1. The commercially available TaqMan systems for FGF1, FGF2, 222 
IL1α, IL1β, IL1R1, TNFα, and βACTIN were purchased from Applied Biosystems. 223 
 224 
2.3. Statistical analyses 225 
Due to the uneven distribution of data obtained by semi-quantitative real-time PCR, 226 
logarithmic transformation was performed to normalize the data and the geometric means 227 
(Xg) ± deviation factors (DF) were calculated for the analysis of target gene expression. The 228 
effects of observational group on target gene expression were then calculated by one-way 229 
analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparison test. 230 
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Since ultrasonography data were normally distributed, one-way ANOVA was performed for 231 
comparisons between early, mid and late luteal phases. 232 
All data were analyzed using the statistical analysis system V9.1 (SAS Institute Inc., Cary, 233 
NC, USA) and the statistical software GraphPad3 (GraphPad Software Inc., San Diego, CA, 234 
USA), respectively. Differences were considered significant at P ≤ 0.05.235 
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3. Results 236 
 237 
3.1. Study 1: Expression of TLR2 and TLR4 in bovine CL throughout the luteal phase 238 
Luteal mRNA expression of TLR2 and TLR4 was detectable in all samples investigated at 239 
selected time points during the luteal phase, revealing a significant effect of time (ANOVA 240 
P < 0.05 and P = 0.02 for TLR2 and TLR4, respectively). Both receptors showed a similar 241 
expression pattern with significantly (P < 0.05) increasing mRNA levels from the early to 242 
mid-luteal phase; no further changes were observed towards the late luteal phase (Fig. 1A, B). 243 
Immunohistochemistry localized the expression of TLR2 and TLR4 predominantly to 244 
steroidogenic cells and luteal blood vessels (Fig. 2). In general, especially in luteal cells, 245 
TLR4 seemed to be more strongly expressed than TLR2, as indicated by more intense staining 246 
of TLR4 which could already be observed during the early luteal phase. During the mid-luteal 247 
phase, the signal intensity appeared stronger with both receptors staining intensively, 248 
especially in large luteal cells. Within blood vessels, the tunica intima and media stained 249 
strongly for both receptors. In particular, vascular endothelial cells clearly revealed positive 250 
signals throughout the luteal phase. 251 
Additionally, the luteal mRNA expression of STAR and 3βHSD was investigated. Their 252 
expression was time-dependent (ANOVA P = 0.002 and P = 0.01 for STAR and 3βHSD, 253 
respectively). It increased (P < 0.01 and P < 0.05, respectively) from the early to mid-luteal 254 
phase, and decreased (each P < 0.05) thereafter to initial values in the late luteal phase 255 
(Supplementary Fig. 1A, B). 256 
Mean LTA was numerically increased (P > 0.05) in the mid-luteal phase compared with the 257 
early and late luteal phase (Supplementary Table 1). There was no significant difference in 258 
absolute and relative LBF as well as plasma P4 concentrations between the early, mid and late 259 
luteal phase. 260 
 261 
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3.2. Study 2: LPS-induced alterations in the expression of TLR2, TLR4 and other luteal 262 
factors 263 
Expression of TLR2 mRNA was higher (P < 0.05) after intravenous LPS-challenge compared 264 
with the control cycle (Fig. 3A). However, mRNA abundance of TLR2 in the estrous cycles 265 
that followed the LPS-challenge cycle and the control cycle did not differ from mRNA 266 
abundance in the LPS-challenge cycle or from that in the control cycle. Luteal mRNA 267 
expression of TLR4 was increased (P < 0.05) after LPS-challenge compared with the control 268 
and subsequent cycles after the LPS-challenge and control cycles (Fig. 3B). There was no 269 
difference in mRNA abundance of TLR4 between the control cycle and the subsequent 270 
(untreated) cycles. Luteal mRNA expression of the steroidogenic factors STAR and 3βHSD 271 
was decreased (P < 0.001) after LPS-challenge compared to the control cycle as well as 272 
compared to the subsequent cycles after the LPS-challenge and control cycles (Fig. 3C, D). 273 
Within prostaglandin-related factors, LPS-challenge significantly increased mRNA 274 
abundance for COX2, mPTGES and 20αHSD/PGFS, but decreased mRNA for PTGFR 275 
(Fig. 4A-D). Specifically, COX2 mRNA expression was higher (P < 0.01) in the LPS-276 
challenge cycle compared to the subsequent cycles after the LPS-challenge and control cycles 277 
but did not differ significantly between the LPS-challenge cycle and control cycle (Fig. 4A). 278 
Luteal expression of mPTGES and 20αHSD/PGFS mRNA was higher (P < 0.001) in the LPS-279 
challenge cycle compared to the control cycle and the subsequent cycle after the control cycle 280 
(Fig. 4B, C). However, mRNA abundance of mPTGES was also higher (P < 0.001) in the 281 
LPS-challenge cycle compared to the subsequent cycle, whereas mRNA abundance of 282 
20αHSD/PGFS in the subsequent cycle after the LPS-cycle did not differ significantly from 283 
the LPS-cycle or from the control cycle. Luteal mRNA expression of PTGFR decreased 284 
(P < 0.001) after LPS-challenge compared to the control and subsequent cycles (Fig. 4D). 285 
Within angiogenic factors, expression of FGF1 mRNA also decreased (P < 0.05) in the LPS-286 
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challenge cycle compared to the control and subsequent cycles, whereas mRNA abundance of 287 
FGF2 increased (P < 0.05) after LPS-challenge compared to the other cycles (Fig. 4E, F). 288 
Expression levels of IL1α and IL1β mRNA were increased (P < 0.001) after LPS-challenge 289 
compared to the control and subsequent cycles (Fig. 5A, B). Luteal mRNA abundance of 290 
IL1R1 was also highest after LPS-challenge but it did not differ from values observed in the 291 
control cycle (Fig. 5C). However, IL1R1 mRNA was more abundant (P < 0.01) in the LPS-292 
cycle compared with the untreated cycle that followed the control cycle. Luteal expression of 293 
TNFα mRNA increased (P < 0.01) after LPS-challenge compared to the control and 294 
subsequent cycles (Fig. 5D). The mRNA abundance of TNFR1 did not differ between cycles, 295 
whereas mRNA for TNFR2 was increased (P < 0.001) in the LPS-cycle compared with the 296 
other cycles (Fig. 5E, F).297 
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4. Discussion 298 
 299 
The results of the present study establish, for the first time, expression patterns of TLR2 and 300 
TLR4 in the bovine CL during the luteal phase. On the mRNA level, the expression of TLR2 301 
and TLR4 has recently been shown in the mid-cycle CL of isolated perfused bovine ovaries in 302 
vitro (Lüttgenau et al. 2016), which could be confirmed in the present ex vivo study. The 303 
cellular localization of both receptors was in steroidogenic cells and luteal vessels, indicating 304 
an immune capability of those cells directed towards components of gram-positive as well as 305 
gram-negative bacteria. Therefore, effects of LPS on the bovine CL do not seem to be 306 
restricted to TLR-bearing immune cells that are normally present in luteal tissue as reported in 307 
a review by Walusimbi & Pate (2013). The localization of TLR4 in luteal cells was consistent 308 
with previous reports that established the presence of TLR4 in granulosa (Herath et al. 2007, 309 
Bromfield & Sheldon 2011, Price & Sheldon 2013) and theca cells (Magata et al. 2014) from 310 
ovarian follicles, which are the progenitors of the large and small luteal cells, respectively 311 
(Alila & Hansel 1984). 312 
The mRNA levels of TLR2 and TLR4 increased from the early towards the mid-luteal phase 313 
and remained unchanged afterwards, i.e., during the late luteal phase. The expression patterns 314 
of STAR and 3βHSD mRNA were determined in order to validate the allocation of CLs to 315 
their respective experimental groups (early, mid or late luteal phase). Increased expression of 316 
STAR and 3βHSD between the early and mid-luteal phase, and decreased expression between 317 
the mid and late luteal phase, were consistent with changes in steroidogenic capacity of the 318 
CL throughout its lifespan (Herzog et al. 2010). Determination of plasma P4 concentrations, 319 
luteal size and blood flow further confirmed that only tissue derived from functional CLs was 320 
used. 321 
Escherichia coli LPS given intravenously increased luteal mRNA expression of TLR2 and 322 
TLR4. Because TLR4 is the receptor for the gram-negative endotoxin LPS (Poltorak et al. 323 
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1998), the increase in TLR4 mRNA might indicate an autoamplification pathway that supports 324 
increased binding of LPS. Binding and activation of TLR4 initiates the production of pro-325 
inflammatory cytokines and leads to the recruitment of leukocytes (Sheldon & Bromfield 326 
2011). However, in the recent study (Lüttgenau et al. 2016) that used isolated perfused 327 
ovaries, luteal mRNA expression of TLR4 did not differ between LPS-treated and control 328 
ovaries during the first 3 h after treatment. Apart from the differences in the general approach 329 
of the recent and the present study (in vitro vs. in vivo), the different outcome in luteal 330 
expression of several factors that were investigated in both studies might be due to the 331 
different sampling time. Whereas biopsies in the present study were performed at 12 h after 332 
treatment, luteal tissue from isolated perfused ovaries was collected during the first 3 h after 333 
challenge because viability of the ovary could not be guaranteed for a longer time. In both 334 
studies, LPS increased TLR2, which typically recognizes bacterial lipids from gram-positive 335 
bacteria (Takeda & Akira 2005). Increased expression of TLR2 mRNA was also observed in 336 
mammary glands challenged with LPS (Ibeagha-Awemu et al. 2008) as well as E. coli (Yang 337 
et al. 2008). Although the reason for increased TLR2 mRNA after LPS treatment is not 338 
known, studies in mice (Matsumura et al. 2000) and humans (Davanian et al. 2012) suggest 339 
that LPS-induced TNFα increases TLR2 mRNA and protein expression. In accordance with 340 
this, in the present study, TNFα mRNA was also increased after LPS-challenge. 341 
The decrease in luteal mRNA expression of steroidogenic factors STAR and 3βHSD after 342 
LPS-challenge was consistent with the transient decrease in plasma P4 concentrations reported 343 
by Herzog et al. (2012). Both STAR and 3βHSD catalyze key steps of steroidogenesis (Couët 344 
et al. 1990, Stocco & Clark 1996) and were inhibited by PGF2α (Stocco et al. 2007). The 345 
increase in mRNA expression of factors related to prostaglandin synthesis (COX2, mPTGES 346 
and 20αHSD/PGFS) was in accordance with increased plasma concentrations of PGFM and 347 
PGE2 after LPS-treatment (Herzog et al. 2012). It is known that pulsatile release of PGF2α 348 
from the uterus or administration of PGF2α increase luteal PGF2α synthesis (Stocco et al. 349 
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2007, Shirasuna et al. 2010). The increase in luteal expression of both luteolytic PGF2α and 350 
luteotropic PGE2 might explain the absence of complete premature luteolysis reported 351 
previously (Herzog et al. 2012). In contrast, luteal mRNA expression of PTGFR was 352 
decreased after LPS-challenge, possibly due to increased PGF2α concentrations, because 353 
PTGFR mRNA was also reduced by PGF2α administration (Shirasuna et al. 2010). 354 
Luteal mRNA expression of FGF1 decreased whereas that of FGF2 increased after LPS-355 
challenge. Fibroblast growth factors are potent mitogens for endothelial cells and other cell 356 
types including luteal cells, and are therefore strong luteotropic factors within the CL 357 
(Yamashita et al. 2008, Shirasuna et al. 2010). The mechanisms that decrease FGF1 but 358 
increase FGF2 remain unknown; however, different expression levels of these luteotropic 359 
factors might have contributed to the incomplete luteolysis observed by Herzog et al. (2012). 360 
In the present study, LPS increased luteal mRNA expression of the proinflammatory 361 
cytokines IL1α, IL1β and TNFα. Increased concentrations of TNFα (in milk and plasma) were 362 
also observed after LPS-induced mastitis (Hoeben et al. 2000). Interleukins and TNFα 363 
mediate the inflammatory response at both the local and systemic levels by promoting 364 
neutrophil transendothelial migration to the site of infection and by inducing fever and the 365 
acute-phase response (Bannerman et al. 2004). Furthermore, IL1α, IL1β and TNFα are potent 366 
stimulators of luteal prostaglandins including PGF2α and PGE2 (Nishimura et al. 2004, 367 
Sakumoto & Okuda 2004). Consistent with this, luteal mRNA expression of 20αHSD/PGFS 368 
and mPTGES was increased after LPS-challenge in the present study. Both TNFα receptors, 369 
TNFR1 and TNFR2, are expressed in the bovine CL (Korzekwa et al. 2008) but only the 370 
mRNA abundance of TNFR2 was increased after LPS-challenge. 371 
In the estrous cycles that followed the LPS-challenge and control cycles, luteal expression of 372 
none of the investigated parameters differed from that observed in the control cycles, 373 
indicating the absence of any carry-over effect of LPS on the CL in the subsequent cycle. 374 
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In conclusion, the expression of TLR2 and TLR4 was predominantly localized to luteal cells 375 
and blood vessels and increased during the mid and late luteal phase. It seems possible that 376 
luteal TLR2 and TLR4 are involved in the immune response of luteal tissue to an intravenous 377 
application of E. coli LPS in vivo, which is associated with the production of proinflammatory 378 
cytokines and reduced ovarian steroidogenesis in cows.379 
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Figure legends 1 
 2 
Fig. 1. Relative levels (Xg ± DF) of luteal mRNA expression of TLR2 (A) and TLR4 (B) 3 
during the early (Days 5 to 7; n=4), mid (Days 8 to 12; n=5) and late (Days 13 to 18; n=5) 4 
luteal phases (Day 1 = ovulation). Parametric ANOVA (P ≤ 0.05) was applied, followed by 5 
the Tukey-Kramer Multiple Comparisons test; (**) indicates P < 0.05. 6 
 7 
Fig. 2. Immunohistochemical localization of TLR2 and TLR4. Representative photographs 8 
are shown at Day 6 (early luteal phase), Day 11 (mid-luteal phase), and at Day 17 (late luteal 9 
phase). Open arrows = luteal cells, solid arrows = luteal vessels. 10 
 11 
Fig. 3. Relative levels (Xg ± DF) of luteal mRNA expression of TLR2 (A), TLR4 (B), STAR 12 
(C), and 3βHSD (D) on Day 10 of the estrous cycle (Day 1 = ovulation) at 12 h after 13 
intravenous treatment with LPS (E. coli O55:B5; 0.5 µg/kgBW) or saline (control), and on 14 
Day 10 of the subsequent (2
nd
) cycle after the LPS-challenge and control cycles. Parametric 15 
ANOVA (P ≤ 0.03) was applied, followed by the Tukey-Kramer Multiple Comparisons test; 16 
a,b
 Values with different superscripts differ (P < 0.05) between the indicated cycles. 17 
 18 
Fig. 4. Relative levels (Xg ± DF) in luteal mRNA expression of COX2 (A), mPTGES (B), 19 
20αHSD/PGFS (C), PTGFR (D), FGF1 (E) and FGF2 (F) on Day 10 of the estrous cycle 20 
(Day 1 = ovulation) at 12 h after intravenous treatment with LPS (E. coli O55:B5; 21 
0.5 µg/kgBW) or saline (control), and on Day 10 of the subsequent (2
nd
) cycle after the LPS-22 
challenge and control cycles. Parametric ANOVA (P ≤ 0.02) was applied, followed by the 23 
Tukey-Kramer Multiple Comparisons test; 
a,b
 Values with different superscripts differ 24 
(P < 0.05) between the indicated cycles. 25 
 26 
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Fig. 5. Relative levels (Xg ± DF) of luteal mRNA expression of IL1α (A), IL1β (B), IL1R1 27 
(C), TNFα (D), TNFR1 (E), and TNFR2 (F) on Day 10 of the estrous cycle (Day 1 28 
= ovulation) at 12 h after intravenous treatment with LPS (E. coli O55:B5; 0.5 µg/kgBW) or 29 
saline (control), and on Day 10 of the subsequent (2
nd
) cycle after the LPS-challenge and 30 
control cycles. Parametric ANOVA (P ≤ 0.006; except for TNFR1 with P > 0.05) was applied, 31 
followed by the Tukey-Kramer Multiple Comparisons test; 
a,b
 Values with different 32 
superscripts differ (P < 0.01) between the indicated cycles. 33 
 34 
Supplementary Fig. 1. Relative levels (Xg ± DF) of luteal mRNA expression of STAR (A) and 35 
3βHSD (B) during the early (Days 5 to 7; n=4), mid (Days 8 to 12; n=5) and late (Days 13 to 36 
18; n=5) luteal phases (Day 1 = ovulation). Parametric ANOVA (P ≤ 0.05) was applied, 37 
followed by the Tukey-Kramer Multiple Comparisons test; (**) indicates P < 0.05, (***) 38 
indicates P < 0.01. 39 
 40 
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Table 1. Accession numbers and sequences of PCR primers for assayed genes from bovine 
corpus luteum cells, and length of PCR products 
 
Primer 
 
Accession 
Numbers 
Primer Sequences Product 
Length 
TLR2 
 
NM_174197 Forward: 5`-TCCACGGACTGTGGTACATGA-3` 
Reverse: 5`-ACACGAAGGCGTCGTAGCA-3` 
TaqMan probe: 5`-CCAGGAAGGCTCCCCGCAGG-3` 
102 
TLR4 
 
NM_174198 
 
Forward: 5`-AAGACTGGGTGCGGAATGAAC-3` 
Reverse: 5`-CCTTACGGCTTTTGTGGAAACC-3` 
TaqMan probe: 5`-TGGCCATCGCCGCCAATATCATC-3` 
144 
STAR NM_174189 Forward: 5`-AAGTCCCTCAAGGACCAAACTC-3` 
Reverse: 5`-TGCGAGAGGACCTGGTTGAT-3` 
TaqMan probe: 5`-ACCTCAAGGGATGGCTGCCGAAGA-3` 
90 
3βHSD 
 
NM_174343 Forward: 5`-CACACCGCCTCTGTCATTGA-3` 
Reverse: 5`-GTACGCTGGCCTGGACACA-3` 
TaqMan probe: 5`-TGCTGTCCCGCGAGACCATCA-3` 
112 
COX2 
(PTGS2) 
 
NM_174445 Forward: 5`-GCACAAATCTGATGTTTGCATTC-3` 
Reverse: 5`-GGTCCTCGTTCAAAATCTGTCT-3` 
TaqMan probe: 5`-TTGCCCAGCACTTCACCCATCAATT-3` 
76 
mPTGES 
(PGES) 
 
NM_174443 Forward: 5`-CAAGTGAGGCTGCGGAAGA-3`  
Reverse: AGGCAGCGTTCCACATCTG-3` 
TaqMan probe: 5`-TTTGCCAACCCCGAGGACGCTC-3` 
101 
20αHSD/ 
PGFS 
(AKR1B5) 
 
NM_001012519 Forward: 5`-ACCTGGACCTCTACCTCATCCA-3` 
Reverse: 5`-TCCTCATCCAATGGGAAGAAGT-3` 
TaqMan probe: 5`-CCCACAGGCTTCAAGCCTGGGA-3` 
73 
PTGFR 
(FP) 
 
NM_181025 Forward: 5`-GCCAACTGGAAGAAGACCTTTC-`3 
Reverse: 5`-CTGGTATGCCTTCATGAGGATAGC-3` 
TaqMan probe: 5`-CAGTGGGAATCTTATCGAACAGCCTGGC-3` 
101 
FGF1 NM_174055.2 Applied Biosystems, prod. nr.: Bt03212662_m1 67 
FGF2 NM_174056.3 Applied Biosystems, prod. nr.: Bt03259205_m1 100 
IL1α 
 
NM_174092 Applied Biosystems, prod. nr.: Bt03212739_m1 94 
IL1β 
 
NM_174093 Applied Biosystems, prod. nr.: Bt03212745_m1 129 
IL1R1 
 
NM_001206735 Applied Biosystems, prod. nr.: Bt04300521_m1 94 
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TNFα NM_173966.3 Applied Biosystems, prod. nr.: Bt03259154_m1 84 
TNFR1 NM_174674.2 Forward: 5`-GTTATGTCCAACCCGACCTTCA-3` 
Reverse: 5`-GGCAAAGCCCGAAGACAAT-3` 
TaqMan probe: 5`-AAGACTCTCAGGACCCAGG-3` 
92 
TNFR2 NM_001040490.2 Forward: 5`-GTCACCGCATGCTTTAGCTGTA-3` 
Reverse: 5`-TGGCTTGCAGGTGCAGATG-3` 
TaqMan probe: 5`-AACTCAAGCCTGCACAAC-3` 
99 
SDHA 
 
NM_174178 Forward: 5`-ATGGAAGGTCTCTGCGCTAT-3` 
Reverse: 5`-ATGGACCCGTTCTTCTATGC-3` 
TaqMan probe: 5`-ACAGAGCGATCACACCGCGG-3` 
119 
GAPDH NM_001034034 Forward: 5`-GCGATACTCACTCTTCTACCTTCGA-3` 
Reverse: 5`-TCGTACCAGGAAATGAGCTTGAC-3` 
TaqMan probe: 5`-CTGGCATTGCCCTCAACGACCACTT-3` 
82 
βACTIN 
 
NM_173979.3 Applied Biosystems, prod. nr.: Bt03279175_g1 144 
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